Product Candidates	Indication	Development Stage				Status
Development Programs		Preclinical	Phase 1	Phase 2	Phase 3
VK2809 (TRb Agonist)	NASH	60%				Phase 2b VOYAGE trial ongoing
VK0214 (TRb Agonist)	X-ALD	35%				Phase 1b
VK2735 (Dual GLP-1/GIP agonist)	Metabolic disorders	35%				Phase 1 ongoing
Other Programs		Preclinical	Phase 1	Phase 2	Phase 3
VK5211 (SARM)	Hip fracture, muscle wasting	60%				Phase 2 completed
VK0612 (FBPase inhibitor)	Type 2 Diabetes	60%				Phase 2a completed
VK1430 (DGAT-1 inhibitor)	Hypertriglyceridemia, NASH	22%				Preclinical

Product/Target	Indication	Phase
VK2809 (TRb Agonist)	NASH	Phase 2
VK0214 (TRb Agonist)	X_ALD	Phase 1
VK5211 (SARM)	Hip fracture, muscle wasting	Phase 2
VK0612 (FBPase inhibitor)	Hip fracture, muscle wasting	Phase 2
VK1430 (DGAT-1 inhibitor)	Hypertriglyceridemia, NASH	Phase 1